As of October 1, 2008 Amgen will no longer offer rebates to oncologists and oncology clinics who purchase Aranesp® (darbepoetin alfa) although they will provide larger discounts at the time of purchase.
They also will no longer base discounts for Neulasta® (pegfilgrastim) and Neupogen© (filgrastim) on purchases of Aranesp, a process known as bundling. Neulasta and Neupogen help raise white cell counts lowered by chemotherapy and are designed to prevent infection resulting from treatment.
Nancy Roach, Chairperson of the C3: Colorectal Cancer Coalition, told the New York Times,
It’s a step in the right direction.
In addition, she told C3 Research News that
C3 supports fair pricing policies for drugs used in cancer treatment that don’t interfere with physicians making the best decision for their patients based on evidence of safety and effectiveness.
Although rebates and discounts are offered by others in the pharmaceutical industry, there was criticism of Amgen’s pricing policies as evidence emerged showing potential safety problems when the drug was used in ways other than indicated on its FDA-approved label.
An Amgen spokesperson told the New York Times that perceptions that physicians might be over-prescribing Aranesp were not true.
Nevertheless, we believe these contracting changes, along with other modifications, help to clear up those possible misperceptions.
For cancer patients, Aranesp is used to prevent blood transfusions in patients who are receiving chemotherapy. An erythropoetin stimulating agent (ESA), it boosts red cell counts. Other ESAs include PROCRIT® and EPOGEN® (epoetin alfa). PROCRIT is sold by Ortho Biotech, EPOGEN by Amgen.
Aranesp, Epogen, and Procrit are not appropriate for cancer patients who are not receiving chemotherapy, and their use should be restricted to the lowest dose possible to prevent blood transfusion. Recent labeling changes also restrict use of ESAs to patients whose cancer treatment is not aimed at a cure. The dosage and administration section of the revised labels state that “Therapy should not be initiated at hemoglobin levels ≥ 10 g/dL.
A revised Medication Guide for patients was also released in August, 2008 reflecting the new labeling and potential for faster tumor growth, shorter survival, and serious cardiovascular side effects.
Leave a Reply
Your comments are welcome. However, specific medical advice will not be provided. Generic QUESTIONS can be directed to our Answer Line team at http://fightcolorectalcancer.org/awareness/answer-line or by calling us at 1-877-427-2111 9:00 AM – 5:00 PM Eastern time, Monday – Friday. We urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. Fight Colorectal Cancer is not responsible for the medical accuracy of any comments left by persons other than Fight Colorectal Cancer staff members. Fight Colorectal Cancer staff members monitor comments and may respond publicly where appropriate.
Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.
We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment.